LAS VEGAS--(BUSINESS WIRE)--CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) today announced that it is launching a new clinical trial to study the safety of a new drug candidate using Cardio Vascu-Grow™ as its active ingredient for the treatment of Peripheral Artery Disease (PAD). Cardio Vascu-Grow™ contains a protein that stimulates the growth and production of new blood vessels, a process called angiogenesis.
